Manuel Pascual

Manuel Pascual is a physician associated with the Transplantation Center of the University Hospital of Lausanne in Lausanne, Switzerland. His contribution in the medical literature assembled here is not a personal narrative but an expert account of chronic HCV infection in kidney transplant recipients. Through that account, he presents the transplant recipient as a patient positioned between two therapeutic necessities: transplantation remains preferable to prolonged dialysis for most patients with end-stage renal disease, yet immunosuppression can intensify viral and hepatic problems and may expose the renal allograft to additional immune-complex and glomerular disease.

Identity and Institutional Role

Manuel Pascual is identified as a member of the Transplantation Center at the University Hospital of Lausanne, with an affiliation also connected to the institution’s infectious-diseases and gastroenterology and hepatology services. His institutional position places him at the intersection of transplantation, nephrology, infectious disease, and liver medicine. That position is reflected in the scope of the work associated with him: the discussion does not isolate HCV as merely a viral laboratory finding, but follows it through screening, liver assessment, dialysis, transplantation, immunosuppressive treatment, graft survival, and post-transplant renal pathology.

The article connected with Pascual describes HCV infection as a major public-health problem and notes that its prevalence is higher among kidney transplant recipients than in the general population. It emphasizes that the natural history of chronic HCV infection after kidney transplantation remains incompletely understood and that clinical management was still difficult because no definite immunosuppressive regimen had demonstrated superiority. Pascual’s role is therefore that of a specialist organizing uncertainty: he identifies what is known, separates it from what remains unresolved, and relates treatment choices to the patient’s broader clinical condition.

Clinical Framework and Transplantation

A central proposition in Pascual’s account is that kidney transplantation should remain the treatment of choice for most HCV-infected patients with end-stage renal disease, even though both patient and graft survival are generally lower than among HCV-negative recipients. The comparison with dialysis is decisive. Transplantation carries risks associated with immunosuppression, liver disease, new-onset diabetes, and recurrent or de novo glomerular disease, but the long-term survival advantage over dialysis means that HCV infection should not automatically exclude a patient from transplantation.

This position is part of a wider clinical pathway in which HCV status must be established accurately before decisions are made. Active chronic infection is not equivalent to antibody positivity alone: diagnosis requires both anti-HCV antibodies and detectable HCV RNA, with molecular assays distinguishing ongoing infection from resolved infection. Once active infection is identified, the liver’s structural and functional condition must be evaluated. Liver biopsy remains the reference method when advanced injury must be staged, although biochemical and noninvasive assessments, including FibroScan-based elastometry, may reduce the need for biopsy and allow repeated monitoring.

The same logic applies to patients awaiting transplantation. Individuals who were never tested should undergo antibody testing with nucleic-acid confirmation in low-prevalence settings, while direct nucleic-acid testing is preferred in high-prevalence settings. A patient with a positive nucleic-acid test should be placed on hold and referred to a hepatologist for evaluation and possible treatment. Patients who have achieved a sustained virologic response require at least annual nucleic-acid testing to confirm that the response persists; those who relapse should again be placed on hold and considered for retreatment. Pascual’s clinical framework thus treats transplantation eligibility as a continuing judgment rather than a one-time administrative decision.

Immunosuppression and Therapeutic Judgment

The question of immunosuppression is the defining problem in Pascual’s work. Immunosuppression may affect HCV replication and the progression of liver disease, but the available evidence does not establish one universally preferable regimen. The appropriate choice must instead be individualized according to immunological risk and comorbidities, including the risk of diabetes mellitus and osteoporosis. This emphasis on individualized treatment rejects the idea that HCV status alone can determine every therapeutic decision.

Induction therapy is not considered contraindicated. A short course may even be beneficial if it reduces acute rejection and thereby prevents the need for high-dose steroid boluses. No clear advantage is established for anti-IL-2 receptor monoclonal antibodies over antithymocyte globulins; the choice should follow the patient’s overall immunological risk. Pascual’s account draws a sharper boundary around OKT3, however, because previous experience associated it with severe hepatitis C, making its administration inappropriate in this population.

Steroid withdrawal may be acceptable for selected patients, particularly those with diabetes mellitus or osteoporosis. At the same time, the long-term effects of maintaining low-dose steroids on liver disease remain uncertain, so withdrawal is not presented as an automatic solution. Mycophenolate mofetil and mycophenolic acid appear safe and should probably be favored over azathioprine, whereas evidence was insufficient to recommend systematic use of mTOR inhibitors. Belatacept had no reported clinical experience in HCV-infected kidney recipients in the period under discussion, and caution was advised with alemtuzumab because intense immunosuppression had been associated with high HCV replication in liver-transplant experience.

Graft Pathology and Patient Outcomes

Pascual’s analysis links HCV to more than hepatic injury. HCV infection is described as an important risk factor for renal allograft loss and remains an independent predictor of graft outcome even in protocol-biopsy studies. Some of this effect may reflect the high immunological risk of the HCV-infected transplant population, which often includes retransplant recipients and patients with prolonged renal disease. Yet the evidence also supports a direct relationship between HCV, autoimmunity, and glomerular injury.

HCV-infected renal and liver allograft recipients are vulnerable to immune-complex-mediated glomerulonephritis. De novo membranoproliferative glomerulonephritis has been reported after transplantation, and later descriptions associated it with type II mixed cryoglobulinemia involving an IgM-kappa monoclonal component. In renal allografts, cryocrit levels are often very low, usually below 5 percent, which can make cryoglobulins difficult to detect or characterize even when HCV RNA is more concentrated in the cryocrit than in serum. The proposed mechanism includes activation of the classical complement pathway.

The clinical picture of HCV-related membranoproliferative glomerulonephritis may include hypertension, microscopic hematuria, proteinuria, renal dysfunction, and sometimes nephrotic syndrome. Biopsy can show mesangial proliferation, double contours, and parietal IgM and C3 deposits. Electron microscopy may be necessary to distinguish this lesion from transplant glomerulopathy: membranoproliferative glomerulonephritis is associated with subendothelial electron-dense deposits, whereas transplant glomerulopathy shows radiolucent alterations in the glomerular basement membrane. The two processes can coexist, illustrating the combined influence of humoral immunity and HCV-related autoimmunity.

The account also records HCV-associated membranous glomerulonephritis in renal allografts, usually with nephrotic syndrome. Its mechanism is less clear because cryoglobulins, immune complexes, and complement activation are often absent. This uncertainty reinforces Pascual’s broader position: the transplant recipient cannot be managed through a single causal model, because viral replication, immune response, graft pathology, and treatment toxicity may overlap without being reducible to one another.

Significance and Limits of the Evidence

Pascual’s significance lies in the balance he maintains between therapeutic optimism and clinical restraint. HCV infection raises the risks of liver disease, diabetes, graft injury, and reduced survival, but it does not erase the survival benefit of transplantation over dialysis. Nor does it justify a rigid immunosuppressive protocol. Decisions must instead move through repeated classification and reassessment: antibody status must be distinguished from active viremia, liver fibrosis must be staged, waiting-list patients must be monitored, and post-transplant renal lesions must be interpreted with both viral and immunological mechanisms in view.

That approach also clarifies why antiviral treatment is most valuable before transplantation when eradication is possible. Post-transplant interferon therapy has been associated with increased allograft rejection, whereas pretransplant sustained virologic response may reduce later complications such as post-transplant diabetes or immune-complex-mediated glomerular disease. Yet treatment can be prolonged, toxic, expensive, and unsuccessful, and patients may need to leave the waiting list during therapy. For patients who remain viremic and cannot undergo or complete treatment, transplantation may still offer a more favorable course than continued dialysis, including the possible use of an HCV-positive donor kidney to shorten waiting time.

The resulting portrait is of Pascual as a clinician-scholar working within an expanding but unsettled field. He does not resolve every controversy surrounding immunosuppression, antiviral therapy, or HCV-positive organs. Instead, he makes the unresolved nature of those controversies clinically useful by showing where evidence is strong, where pathology complicates interpretation, and where individualized judgment remains indispensable. His work turns the HCV-infected kidney recipient into neither a contraindication nor a simple high-risk category, but into a patient whose survival, graft, liver, immune system, and access to scarce organs must be considered as one connected medical problem.